Navigation Links
PneumRx, Inc. Announces CE Mark Approval for Its RePneu® Lung Volume Reduction Coil (LVRC™) System
Date:10/13/2010

MOUNTAIN VIEW, Calif., Oct. 13 /PRNewswire/ -- PneumRx, Inc. (www.pneumrx.com), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has received CE Mark approval for its RePneu Lung Volume Reduction Coil (LVRC) System to treat the later stages of emphysema.  

The RePneu LVRC System is a minimally invasive device intended to improve lung function in emphysema patients by brochoscopically implanting Nitinol coils into the lungs to compress damaged tissue (lung volume reduction) and restore elastic recoil to the healthier lung tissue.  This treatment offers a minimally invasive alternative to lung volume reduction surgery, and works independently of collateral ventilation.  

The CE mark approval enables PneumRx to move forward with commercialization in Europe and other select markets.  PneumRx intends to launch its RePneu LVRC System in Europe in the last quarter of 2010.  PneumRx plans to continue its ongoing partnership with physicians through training and by offering novel products for the diagnosis and treatment of lung disease.

"We are thrilled to have achieved this important milestone, and look forward to introducing our RePneu LVRC to the European market to help improve the lives of so many people who are suffering from emphysema and have few other viable treatment options," said Erin McGurk, President and CEO of PneumRx, Inc.  "We are extremely pleased with the significant improvements in pulmonary function tests, exercise tolerance, and quality of life experienced by our clinical trial patients, and expect to bring these same benefits to a broader population of emphysema patients with the commercialization of the RePneu LVRC System in Europe."

About PneumRx, Inc.

PneumRx, Inc. is a rapidly growing medical device company focused on the development and commercialization of innovative products to treat emphysema using minimally-invasive techniques.  It is a privately held company located in Mountain View, California.


'/>"/>
SOURCE PneumRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 30, 2017  Lannett Company, Inc. (NYSE: ... a $25 million payment against its existing revolving credit ... with the $75 million payment we made earlier this ... in annualized cash interest expense, at current rates" said ... "Our business is solid and we continue to generate ...
(Date:3/30/2017)... Revenue Prospects by Product Type (Metered Dose Inhalers, Dry ... Respiratory Inhalers - our new study reveals trends, R&D progress, ... If you are involved in this sector you must read this ... revenues streams to 2027, assessing data, trends, opportunities and business prospects ... Discover how ...
(Date:3/30/2017)... , March 30, 2017  Purcell Julie & Lefkowitz LLP, ... is investigating a potential breach of fiduciary duty claim involving ... SGYP ). If you are a ... information regarding this investigation, free of charge, please visit us ... ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... , ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag ... network of more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, ... mowers and cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, the ... New York City-based sports and entertainment marketing firm Leverage Agency as its exclusive ... the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming rights, ...
(Date:3/29/2017)... ... 30, 2017 , ... Grass pollen is the main cause of hay fever in the United ... for grass pollen runs from May to July each year; with the worst time for ... HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they ...
(Date:3/29/2017)... ... ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program in ... who have participated in the program every summer. The 2017 Serve, Learn, & ... enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent my ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Sports Brand EXOUS ... brace, which retails normally at $29.97; for the remaining days of March, the price ... been reduced to a special price of just $10 (regular retail price $19.97). , ...
Breaking Medicine News(10 mins):